PV

Prudence Venture Investment Corporation

Description

Prudence Venture Investment Corporation is a principal investment firm focused on investments in real estate and financial services.

Investor Profile

Prudence Venture Investment Corporation has made 2 investments, with 0 in the past 12 months and 0% as lead.

Stage Focus

  • Series Unknown (50%)
  • Series B (50%)

Country Focus

  • United States (100%)

Industry Focus

  • Biopharma
  • Biotechnology
  • Therapeutics
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Prudence Venture Investment Corporation frequently co-invest with?

DeNovo Ventures
North America, California, United States, Saratoga
Co-Investments: 2
Pac-Link
Asia, T'ai-pei, Taiwan, Taipei
Co-Investments: 2
BL
Asia, T'ai-pei, Taiwan, Taipei
Co-Investments: 2
CMEA Ventures
North America, California, United States, San Francisco
Co-Investments: 2
Montreux Equity Partners
North America, California, United States, San Francisco
Co-Investments: 2
Quintiles
North America, North Carolina, United States, Durham
Co-Investments: 2
Morgenthaler Ventures
North America, California, United States, Menlo Park
Co-Investments: 2
Latterell Venture Partners
North America, California, United States, San Francisco
Co-Investments: 2
Lilly Ventures
North America, Indiana, United States, Indianapolis
Co-Investments: 2
Pappas Ventures
North America, North Carolina, United States, Durham
Co-Investments: 2

What are some of recent deals done by Prudence Venture Investment Corporation?

Bayhill Therapeutics

Portola Valley, California, United States

Bayhill Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapeutics.

BiopharmaBiotechnologyTherapeutics
Series UnknownApr 11, 2006
Amount Raised: $15,800,000
Bayhill Therapeutics

Portola Valley, California, United States

Bayhill Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapeutics.

BiopharmaBiotechnologyTherapeutics
Series BMay 4, 2005
Amount Raised: $35,400,000